PHAR · Pharming Group NV ADR
United States · RS rating 70 · As of 2026-11-03
| Price | 12.93 USD |
|---|---|
| 1-day change | +1.6% |
| RS rating (overall / 1M / 3M / 12M) | 70 / 97 / 90 / 50 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 34 / 23 / 25 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -200.0% |
| Sales growth Q/Q | +109369.9% |
| Distance from 52-week high | +39.0% |
| Market cap (USD) | $1.2B |